AbbVie Inc. (TSX:ABBV)

Market Cap	570.30B
Revenue (ttm)	83.08B
Net Income (ttm)	3.27B
Shares Out	n/a
EPS (ttm)	1.84
PE Ratio	174.38
Forward PE	17.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,706
Average Volume	6,906
Open	32.13
Previous Close	31.21
Day's Range	32.12 - 33.33
52-Week Range	23.68 - 34.48
Beta	n/a
RSI	58.24
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD